Compare OMAB & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMAB | GKOS |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.9B |
| IPO Year | N/A | 2015 |
| Metric | OMAB | GKOS |
|---|---|---|
| Price | $110.81 | $108.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $106.00 | ★ $133.07 |
| AVG Volume (30 Days) | 71.4K | ★ 684.4K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $10.31 | $23.39 |
| Revenue Next Year | $12.39 | $27.46 |
| P/E Ratio | $21.86 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $70.24 | $73.16 |
| 52 Week High | $134.99 | $130.23 |
| Indicator | OMAB | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 35.22 | 39.14 |
| Support Level | $99.42 | $104.72 |
| Resistance Level | $111.48 | $115.06 |
| Average True Range (ATR) | 4.86 | 4.81 |
| MACD | -2.55 | -0.91 |
| Stochastic Oscillator | 7.84 | 22.95 |
Grupo Aeroportuario del Centro Norte SAB de CV operates airports in the central region of Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages two hotels and one industrial park. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, individually, and information about its holding company and other companies is combined in the Others.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.